337 related articles for article (PubMed ID: 33024022)
1. Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a.
Bovis F; Kalincik T; Lublin F; Cutter G; Malpas C; Horakova D; Havrdova EK; Trojano M; Prat A; Girard M; Duquette P; Onofrj M; Lugaresi A; Izquierdo G; Eichau S; Patti F; Terzi M; Grammond P; Bergamaschi R; Sola P; Ferraro D; Ozakbas S; Iuliano G; Boz C; Hupperts R; Grand'Maison F; Oreja-Guevara C; van Pesch V; Cartechini E; Petersen T; Altintas A; Soysal A; Ramo-Tello C; McCombe P; Turkoglu R; Butzkueven H; Wolinsky JS; Solaro C; Sormani MP
Neurology; 2021 Jan; 96(2):e214-e227. PubMed ID: 33024022
[TBL] [Abstract][Full Text] [Related]
2. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
[TBL] [Abstract][Full Text] [Related]
3. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
Saida T; Kira J; Ueno Y; Harada N; Hirakata T
Mult Scler Relat Disord; 2016 May; 7():102-8. PubMed ID: 27237769
[TBL] [Abstract][Full Text] [Related]
5. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
6. Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis.
Becker RV; Dembek C
J Manag Care Pharm; 2011 Jun; 17(5):377-81. PubMed ID: 21657808
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.
Lublin FD; Cofield SS; Cutter GR; Gustafson T; Krieger S; Narayana PA; Nelson F; Salter AR; Wolinsky JS
Mult Scler Relat Disord; 2017 Nov; 18():95-102. PubMed ID: 29141831
[TBL] [Abstract][Full Text] [Related]
8. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
[TBL] [Abstract][Full Text] [Related]
9. Utilization of peginterferon-β-1a in the real-world practice for relapsing-remitting multiple sclerosis.
Moccia M; Santoni L; Vaccari I; Affinito G; Caliendo D; Rubba F; Lanzillo R; Triassi M; Brescia Morra V; Palladino R
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(1):411-418. PubMed ID: 38235893
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
[TBL] [Abstract][Full Text] [Related]
11. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.
Darbà J; Kaskens L; Sánchez-de la Rosa R
J Med Econ; 2014 Mar; 17(3):215-22. PubMed ID: 24494728
[TBL] [Abstract][Full Text] [Related]
13. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
Roskell NS; Zimovetz EA; Rycroft CE; Eckert BJ; Tyas DA
Curr Med Res Opin; 2012 May; 28(5):767-80. PubMed ID: 22462530
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
Dashputre AA; Kamal KM; Pawar G
J Manag Care Spec Pharm; 2017 Jun; 23(6):666-676. PubMed ID: 28530523
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Stable Multiple Sclerosis Patients Staying on Initial Interferon Beta Therapy Versus Switching to Another Interferon Beta Therapy: A US Claims Database Study.
Cohan S; Smoot K; Kresa-Reahl K; Garland R; Yeh WS; Wu N; Watson C
Adv Ther; 2018 Nov; 35(11):1894-1904. PubMed ID: 30341505
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis.
Zhang J; Shi S; Zhang Y; Luo J; Xiao Y; Meng L; Yang X
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD010968. PubMed ID: 29178444
[TBL] [Abstract][Full Text] [Related]
17. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
[TBL] [Abstract][Full Text] [Related]
18. Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study.
Lus G; Signoriello E; Maniscalco GT; Bonavita S; Signoriello S; Gallo C
Eur J Neurol; 2016 Mar; 23(3):489-93. PubMed ID: 26212486
[TBL] [Abstract][Full Text] [Related]
19. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
[TBL] [Abstract][Full Text] [Related]
20. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]